Segment Information

3 Months Ended

Mar. 30, 2024

Segment Reporting [Abstract]

Segment Information

Note 17: Segment Information

The Company operates within targeted markets through two reportable segments for continuing operations: biotechnology and recycling. The Biotechnology segment commenced operations in September 2019 and is focused on development of new and innovative solutions for ending the opioid epidemic ranging from digital technologies to educational advocacy. The Recycling segment includes all fees charged and costs incurred for collecting, recycling and installing appliances for utilities and other customers. The Recycling segment also includes byproduct revenue, which is primarily generated through the recycling of appliances. The nature of products, services and customers for each segment varies significantly. As such, the segments are managed separately. Our Chief Executive Officer has been identified as the Chief Operating Decision Maker (“CODM”). The CODM evaluates performance and allocates resources based on sales and income from operations of each segment. Operating loss represents revenues less cost of revenues and operating expenses, including certain allocated selling, general and administrative costs. There are no intersegment sales or transfers. Due the sale of

Company's Recycling segment during March 2023, it is being presented as discontinued operations for the 13 weeks ended April 1, 2023.

The following tables present the Company's segment information for the 13 weeks ended March 30, 2024 and April 1, 2023 (in $000's):

	Thirteen Weeks Ended
	March 30, 2024		April 1, 2023
Revenues
Biotechnology	$	—	$	—
Discontinued operations	—		3,795
Total Revenues	$	—	$	3,795
Gross profit
Biotechnology	$	—	$	—
Discontinued operations	—		(197)
Total Gross profit	$	—	$	(197)
Operating loss
Biotechnology	$	(1,806)	$	(1,099)
Discontinued operations	—		14,158
Total Operating loss	$	(1,806)	$	13,059
Depreciation and amortization
Biotechnology	$	—	$	364
Discontinued operations	—		96
Total Depreciation and amortization	$	—	$	460
Interest (income) expense, net
Biotechnology	$	252	$	(475)
Discontinued operations	—		181
Total Interest expense, net	$	252	$	(294)
Net income (loss) before income taxes
Biotechnology	$	(2,219)	$	(889)
Discontinued operations	—		13,976
Total Net income before income taxes	$	(2,219)	$	13,087